QUEBEC CITY, Oct. 8, 2013 /PRNewswire/ – Atrium Innovations Inc. (TSX: ATB) (“Atrium” or the “Company”), a globally recognized leader
in the development, manufacturing, and commercialization of innovative,
science-based natural health products, announced today that it has
acquired 70% of the outstanding shares of Mucos Pharma CZ s.r.o. (“Mucos CZ”), the exclusive distributor of Wobenzym products in Central and Eastern Europe.

Over the past few years, the solidly established Mucos CZ has
successfully distributed Wobenzym products primarily in Russia, Czech Republic and Slovakia. This controlling
interest in Mucos CZ reflects the strategic importance of Central and
Eastern European markets to Atrium in reference to Wobenzym’s potential
and the potential for future cross-selling opportunities particularly
in Russia.

The transaction includes an obligation on or before December 31, 2015 to
acquire the remaining 30% of Mucos CZ shares allowing for a proper
transition. The acquisition price of this transaction is established on
a multiple of 4.75 times the last twelve months EBITDA. This
transaction of US$15.9 million will be financed with existing credit
facilities.

“We have a longstanding relationship with Mucos CZ which has focused
solely on selling Wobenzym,” said Pierre Fitzgibbon, President and CEO of Atrium. “Mucos CZ has
been a distributor of Wobenzym products over the last 20 years. Our intention is to integrate this
platform to solidify our Wobenzym business and to introduce other Atrium products particularly in Russia.
The transaction will be accretive to net income immediately following
the depletion of the inventory purchased by Mucos CZ prior to the
transaction. Consequently, our fourth quarter 2013 gross and EBITDA
margins on a consolidated basis will be temporarily negatively
impacted.”

About Atrium Innovations
Atrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and
commercialization of innovative, science-based natural health products
which are distributed in more than 35 countries. The Company owns
healthcare practitioner and specialized retail product brands that are
at the forefront of science, innovation and education. Atrium has over
1,100 employees and operates seven manufacturing facilities complying
with current Good Manufacturing Practices. Additional information is
available at www.atrium-innovations.com.

Cautionary Note and Forward-Looking Statements

This press release contains certain forward-looking statements with
respect to the Company. These forward-looking statements, by their
nature, require the Company to make certain assumptions and necessarily
involve known and unknown risks and uncertainties that could cause
actual results to differ materially from those expressed or implied in
these forward-looking statements. Forward-looking statements are not
guarantees of performance. These forward-looking statements, including
financial outlooks, may involve, but are not limited to, comments with
respect to the Company’s business or financial objectives, its
strategies or future actions, its targets, expectations for financial
condition or outlook for operations and future contingent payments.
Words such as “may”, “will”, “would”, “could”, “expect”, believe”,
“plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative
or comparable terminology, as well as terms usually used in the future
and the conditional, are intended to identify forward-looking
statements. Information contained in forward-looking statements is
based upon certain material assumptions that were applied in drawing a
conclusion or making a forecast or projection, including management’s
perceptions of historical trends, current conditions and expected
future developments, as well as other considerations that are believed
to be appropriate in the circumstances. The Company considers theses
assumptions to be reasonable based on information currently available
to it, but cautions the reader that these assumptions regarding future
events, many of which are beyond its control, may ultimately prove to
be incorrect since they are subject to risks and uncertainties that
affect the Company and its business.

For additional information with respect to these and other factors and
assumptions underlying the forward-looking statements made in this
press release, see the Company’s quarterly and annual Management
Discussion and Analysis filed with the Canadian securities commissions.
The forward-looking information set forth herein reflects the Company’s
expectations as at the date of this press release and is subject to
change after such date. The Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, other than
as required by law.

SOURCE ATRIUM INNOVATIONS INC.